• General Dermatology
  • Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management

Impact of PP Comorbidities


Tj Chao, MPAS, and Lauren Miller, MPAS, highlight comorbidities that caregivers should consider when treating patients with plaque psoriasis (PP).


Lauren Miller, MPAS, PA-C: What does the presence of comorbidities do when it comes to your plan of action and your therapeutic choice for your patients?

TJ Chao, MPAS, PA-C: I think the most important one would be psoriatic arthritis.

Lauren Miller, MPAS, PA-C: I agree.

TJ Chao, MPAS, PA-C: If they have psoriatic arthritis, that’s going to have the biggest impact on decision-making. In those patients, I may lean more toward anti-TNFs [tumor necrosis factor inhibitors] or IL-17s [interleukin-17 inhibitors] in the treatment of their disease to get better control over their joints and skin. Now, if you have patients who have inflammatory bowel disease, you may want to stay away from IL-17s. That’s something that could potentially have an impact on the patient. Also, I would say if they have a lot of inflammatory conditions, heart disease, things like that, you may want to consider being potentially more aggressive with systemic agents.

Lauren Miller, MPAS, PA-C: True. I think you have to take into account, I like to look at it as a big picture. It’s a big puzzle, and you have to put each individual little piece in with it. I think we all have our own algorithm, but every patient is so different that there isn’t a one-size-fits-all [answer] when it comes to trying to choose a therapeutic. There are lots of options that a single patient could potentially be on. But I agree with you 100%, you have to take into account comorbidities because we’re thinking about safety, obviously.

Transcript edited for clarity.

Related Videos
4 KOLs are featured on this panel.
4 KOLs are featured on this panel.
4 KOLs are featured on this panel.
4 KOLs are featured on this panel.
© 2024 MJH Life Sciences

All rights reserved.